Tumor immunophenotyping 1 week after treatment indicated loss of Foxp3+ regulatory T (Treg) cells in response to CTLA4 across genotypes (Fig. 5h and Extended Data Fig. 4f–i). This evidence concerns the gene FOXP3 and neoplasm.